Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2023 Earnings Call Transcript

And I think that the SYFOVRE experience is a lovely example of this. The benefit is very small. Thus, a small risk is causing a lot of heartache for that program. If you have an enormous clinical benefit, and I think it’s fair to say that the things that we have shown in patients, especially now with today’s update of two-year data, is exactly that. It’s an enormous benefit with vision going in the opposite direction of what is expected. I think that does give you some greater permissibility with respect to safety because the surgical intervention, I presume, will always be more complex and lead to more adverse events than a simple injection into the eye, I will say that we don’t have polyethylene glycol in our formulation. So we don’t have to worry about the particular issue that SYFOVRE and Apellis are dealing with.

However, it is still a surgery. And so infrequent surgical events, that are occurring with these kinds of interventions probably can be reduced with effort, but probably will never go completely away. And that will ultimately be part of the product profile and the package insert and black boxes are relevant for different products. That’s how those things get addressed and ultimately, their adoption by the surgeon and by the patient is going to determine whether it’s successful or not. What I feel particularly good about is that the clinical benefit that we’re showing has been very significant the product to date has been well tolerated in the patients that have received it. We have, to my knowledge, received no notices or reports a rejection of our cells, no notices of reports of cysts or tumors or the other kinds of things that people sometimes worry about.

And with every passing day, it increasingly looks like a onetime intervention. And that is a product profile that I think is going to win the day every single time.

Joe Pantginis : Very helpful. Thanks, again.

Brian Culley : You’re welcome, Joe. Thanks for the question.

Operator: This concludes our Q&A session. I will now turn the call over to Mr. Brian Culley for closing remarks.

Brian Culley : I have nothing more to add today, John. Thank you very much.

Operator: I would like to thank our speakers for today’s presentation. And thank you all for joining us. This now concludes today’s conference. You may now disconnect.